866-997-4948(US-Canada Toll Free)

Endometrial Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 133 Pages


Global Markets Directs, 'Endometrial Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Endometrial Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Endometrial Cancer. 

Endometrial Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Endometrial Cancer.
  • A review of the Endometrial Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Endometrial Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Endometrial Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Endometrial Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Endometrial Cancer Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Endometrial Cancer 8
Endometrial Cancer Therapeutics under Development by Companies 10
Endometrial Cancer Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Endometrial Cancer Therapeutics - Products under Development by Companies 19
Endometrial Cancer Therapeutics - Products under Investigation by Universities/Institutes 21
Companies Involved in Endometrial Cancer Therapeutics Development 23
Bristol-Myers Squibb Company 23
Sanofi-Aventis 24
AstraZeneca PLC 25
GlaxoSmithKline plc 26
Genentech, Inc. 27
Daiichi Sankyo Company, Ltd 28
Merck & Co., Inc. 29
Novartis AG 30
Eisai Co., Ltd. 31
Pfizer Inc. 32
EntreMed, Inc. 33
AEterna Zentaris Inc. 34
Critical Outcome Technologies Inc. 35
Oryzon 36
Acceleron Pharma, Inc. 37
Esperance Pharmaceuticals, Inc. 38
Anaphore, Inc. 39
Aragon Pharmaceuticals, Inc. 40
Endometrial Cancer - Therapeutics Assessment 41
Assessment by Monotherapy Products 41
Assessment by Combination Products 42
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 48
AEZS-108 - Drug Profile 48
lenvatinib - Drug Profile 50
RG-7422 - Drug Profile 52
PF-05212384 - Drug Profile 53
ridaforolimus - Drug Profile 54
MKC-1 - Drug Profile 58
dalantercept - Drug Profile 60
fulvestrant - Drug Profile 62
iniparib - Drug Profile 63
COTI-2 - Drug Profile 65
EP-100 - Drug Profile 66
dovitinib lactate - Drug Profile 68
vatalanib + [docetaxel] - Drug Profile 70
bevacizumab + Radiation Therapy - Drug Profile 71
everolimus - Drug Profile 72
buparlisib - Drug Profile 73
bevacizumab + [carboplatin] + [paclitaxel] - Drug Profile 76
Taxotere + Paraplatin - Drug Profile 77
brivanib alaninate - Drug Profile 78
bevacizumab + [carboplatin]+ [ixabepilone] - Drug Profile 79
GSK-2141795 + trametinib - Drug Profile 81
Docetaxel + Cisplatin - Drug Profile 82
COTI-2 + [paclitaxel albumin-bound] - Drug Profile 83
AEZS-132 - Drug Profile 85
ixabepilone - Drug Profile 86
Docetaxel + Carboplatin - Drug Profile 87
nintedanib - Drug Profile 88
X-480 - Drug Profile 89
EP-200 - Drug Profile 90
MK-2206 - Drug Profile 91
DS-7423 - Drug Profile 93
trastuzumab + [carboplatin] + [paclitaxel] - Drug Profile 94
ARGX-109 - Drug Profile 96
E39 Peptide Vaccine - Drug Profile 97
TP-0227 - Drug Profile 98
Monoclonal Antibody For Endometrial Cancer - Drug Profile 99
dalantercept - Drug Profile 100
ONCO-101 - Drug Profile 101
ARN-912 - Drug Profile 102
Endometrial Cancer Therapeutics - Drug Profile Updates 103
Endometrial Cancer Therapeutics - Discontinued Products 119
Endometrial Cancer Therapeutics - Dormant Products 120
Endometrial Cancer - Product Development Milestones 122
Featured News & Press Releases 122
Appendix 129
Methodology 129
Coverage 129
Secondary Research 129
Primary Research 129
Expert Panel Validation 129
Contact Us 130
Disclaimer 130

List of Table


Number of Products Under Development for Endometrial Cancer, H1 2013 11
Products under Development for Endometrial Cancer - Comparative Analysis, H1 2013 12
Number of Products under Development by Companies, H1 2013 14
Number of Products under Development by Companies, H1 2013 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2013 17
Comparative Analysis by Late Stage Development, H1 2013 18
Comparative Analysis by Mid Clinical Stage Development, H1 2013 19
Comparative Analysis by Early Clinical Stage Development, H1 2013 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 21
Products under Development by Companies, H1 2013 22
Products under Development by Companies, H1 2013 (Contd..1) 23
Products under Investigation by Universities/Institutes, H1 2013 24
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 25
Bristol-Myers Squibb Company, H1 2013 26
Sanofi-Aventis, H1 2013 27
AstraZeneca PLC, H1 2013 28
GlaxoSmithKline plc, H1 2013 29
Genentech, Inc., H1 2013 30
Daiichi Sankyo Company, Ltd, H1 2013 31
Merck & Co., Inc., H1 2013 32
Novartis AG, H1 2013 33
Eisai Co., Ltd., H1 2013 34
Pfizer Inc., H1 2013 35
EntreMed, Inc., H1 2013 36
AEterna Zentaris Inc., H1 2013 37
Critical Outcome Technologies Inc., H1 2013 38
Oryzon, H1 2013 39
Acceleron Pharma, Inc., H1 2013 40
Esperance Pharmaceuticals, Inc., H1 2013 41
Anaphore, Inc., H1 2013 42
Aragon Pharmaceuticals, Inc., H1 2013 43
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Stage and Molecule Type, H1 2013 50
Endometrial Cancer Therapeutics - Drug Profile Updates 106
Endometrial Cancer Therapeutics - Discontinued Products 122
Endometrial Cancer Therapeutics - Dormant Products 123
Endometrial Cancer Therapeutics - Dormant Products (Contd..1) 124

List of Chart


Number of Products under Development for Endometrial Cancer, H1 2013 11
Products under Development for Endometrial Cancer - Comparative Analysis, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 16
Late Stage Products, H1 2013 18
Mid Clinical Stage Products, H1 2013 19
Early Clinical Stage Products, H1 2013 20
Discovery and Pre-Clinical Stage Products, H1 2013 21
Assessment by Monotherapy Products, H1 2013 44
Assessment by Combination Products, H1 2013 45
Assessment by Route of Administration, H1 2013 46
Assessment by Stage and Route of Administration, H1 2013 47
Assessment by Molecule Type, H1 2013 48
Assessment by Stage and Molecule Type, H1 2013 49

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *